Publications

BACKGROUND: The lateral upper arm (LUA) pathway is a route of superficial lymphatic drainage that bypasses the axilla by draining to the deltopectoral, clavicular, and cervical lymph nodes. Despite the fact that anatomic variations of the LUA pathway have been implicated in breast cancer-related lymphedema (BCRL) risk after axillary lymph node dissection (ALND), the incidence of the LUA pathway variations in the healthy population has never been reported.

METHODS: Healthy female volunteers underwent bilateral lymphatic mapping of the upper extremities with indocyanine green (ICG) lymphography. ICG was injected in six standard sites in the hand/wrist and upper arm. Major anatomic variations of the LUA pathway were recorded including bundle phenotype (long, short, or absent), proximal visualization sites, and forearm pathway continuation to the long bundle phenotype.

RESULTS: 90 arms of 45 volunteers were included. The LUA pathway was present in 99% of arms and a long-versus-short bundle phenotype was observed in 71% versus 28% of arms. When the long bundle was present, it was formed by continuity with the forearm posterior radial channel alone (47%), posterior ulnar channel alone (34%), or both channels (19%). The LUA pathway was traced proximally to the deltopectoral groove in 89% of arms and to the axilla in 11% of arms.

CONCLUSIONS: We observed similar proportions of arms with long and short bundle phenotypes in comparison to our previous report of the LUA pathway in breast cancer patients with nodal disease. Defining the incidence of the LUA pathway with its variations in the general population is important as variations in this pathway may have implications for an individual's risk of developing BCRL.

OBJECTIVE: Assess the incidence and clinical outcomes of inadvertent bowel sampling with a 17-G coaxial system with an 18-G semi-automatic biopsy needle, omental and mesenteric CT and US-guided biopsy.

METHODS: In this retrospective study, consecutive patients undergoing omental and mesenteric CT and US-guided biopsy with a 17-G introducer, an 18-G semi-automatic biopsy device performed at a single tertiary academic institution between March 1, 2005, and March 1, 2024, were included to assess the incidence and clinical outcomes of inadvertent bowel sampling. Descriptive statistics were used.

RESULTS: Among 265 biopsies, there were six cases (6/265, 2.3%) with inadvertent bowel sampling identified on pathology. The median age was 83.5 years (IQR: 65.6-85.3) in patients with inadvertent bowel sampling, and 66 years (IQR: 58-74) in patients without inadvertent bowel sampling, p = 0.02. In patients with inadvertent bowel sampling, 4/6 (66.7%) of biopsies were from mesentery, in contrast to the patients without inadvertent bowel sampling, with 210/259 (81.1%) omental biopsies, p: 0.04. The bowel mucosa on pathology was arising from the colon in 3/6 (50%), the duodenum in 2/6 (34%), and the distal ileum in 1/6 (17%). All patients underwent a standard post-procedure observation time of 1 hour, during which no signs or symptoms of clinically significant bowel perforations were identified. No patients were admitted after the procedure, and no patients required admission within 30 days after the procedure for bowel-related indications.

CONCLUSION: Inadvertent bowel sampling during percutaneous omental and mesenteric biopsy with a 17 G introducer, and an 18 G semi-automatic needle is a rare, but likely benign event, even in patients without bowel preparation or antibiotic coverage.

KEY POINTS: Question The incidence and clinical consequences of unintended intestinal sampling in percutaneous omental and mesenteric core needle biopsies are unknown. Findings Inadvertent bowel sampling occurred in 2.3% of omental and mesenteric biopsies. No clinically significant complication was observed, despite the lack of bowel preparation or antibiotic prophylaxis. Clinical relevance Inadvertent bowel sampling is rare, more common in elderly patients and mesenteric biopsies, and likely benign, even without preparatory measures. However, given the potential for serious complications reported in the literature, meticulous technique remains crucial to minimizing the risk.

Pulmonary embolism is a common cause of cardiovascular-associated morbidity and mortality. Although pulmonary embolism affects individuals from all demographics, the incidence of pulmonary embolism is higher among people from certain racial groups, reproductive-age women compared with age-matched men, and transgender people taking estrogen hormones. Furthermore, disparities may exist in the diagnosis or management strategies of pulmonary embolism associated with race, ethnicity, sex, or socioeconomic status, which may correlate with poorer downstream outcomes, including recurrent pulmonary embolism, chronic thromboembolic pulmonary hypertension, or short- or long-term mortality. This scientific statement summarizes disparities in diagnosis, treatment strategies, and outcomes related to pulmonary embolism, and reviews approaches to create equitable pulmonary embolism care and address the knowledge gaps in the literature.

PURPOSE: To assess whether causes of moral distress vary by academic institution. Moral distress is experienced when health care providers are unable to provide the right care to patients because of institutional or resource constraints.

MATERIALS AND METHODS: A survey was performed based on Moral Distress Scale-Revised for Health Care Professionals for 16 clinical scenarios assessing frequency and severity of moral distress among academic radiologists. The survey was sent to members of the RSNA Quality Improvement Committee for distribution to their department. Measure of Moral Distress for Health Care Professionals (MMD-HP) was calculated for individuals and moral distress index for clinical scenarios. MMD-HP were compared by sex, ethnicity, age, years of practice, weekly work hours, practice setting or type, and consideration of leaving the workplace. Statistical analysis was performed using Kruskal-Wallis test and Kendall ordinal correlation.

RESULTS: In all, 126 respondents from five institutions from five different states were included in the analysis. MMD-HP ranged from 24 to 66 (maximum 266). Median MMD-HP was higher in radiologists working >60 hours per week (59 versus 32.5, P = .048). Radiologists across institutions consistently reported four main sources of moral distress: pressure to perform unsafe numbers of studies (108 of 126, 85%), high workloads impeding resident teaching (102 of 126, 81%), lack of administrative support for patient care issues (102 of 126, 81%), and pressure to conduct unnecessary imaging (111 of 126, 88%). Higher MMD-HPs correlated significantly with job turnover intentions or past job changes (P < .001). The average percentage of radiologists with an intention to leave or having left as position was 44% with a range of 26% to 84%.

CONCLUSION: Moral distress is pervasive in radiology, with four primary causes consistently identified across academic institutions. Strong association between higher moral distress levels and job turnover intentions highlights its impact on workforce retention.

BACKGROUND AND PURPOSE: Neuromix is a fast, motion robust multi-contrast sequence capable of providing all diagnostic contrasts in ∼3.5 minutes. However, more evaluation is needed across the various contrasts compared to gold standard, optimized sequences routinely used in the clinic. The goal of this study was to prospectively determine how NeuroMix performs in the clinical setting compared to routine clinical MRI.

METHODS: NeuroMix and routine clinical MRI sequences were acquired on a 3 Tesla clinical scanner for 39 patients clinically indicated for brain MRI. Three radiologists were asked to assess the diagnostic confidence of NeuroMix compared to the routine MRI using a series of questions. Signal-to-noise and contrast-to-noise ratios (SNR and CNR) were assessed for NeuroMix. Fleiss' free-marginal multirater kappa was calculated for the qualitative assessment performed by the radiologists.

RESULTS: Radiologists were comfortable substituting or reading some of the NeuroMix sequences in place of the corresponding conventional sequence for some contrasts, including diffusion-weighted imaging, single-shot T2, and susceptibility-weighted imaging. The image quality, SNR, and CNR allowed the radiologists to visualize anatomy and pathology on NeuroMix images. There was no significant difference between coefficient of variation for the apparent diffusion coefficient maps (p = .084).

CONCLUSIONS: Analysis revealed both positives and some pitfalls of NeuroMix. However, these results indicate Neuromix as having the capability to be a backup sequence in case artifacts are present in routine sequences, or potentially a replacement for some contrasts altogether.

Hepatocellular carcinoma is a leading and increasing contributor to cancer-related death worldwide. Recent advancements in both liver-directed therapies in the form of yttrium-90 (90Y) radioembolization (RE) and systemic therapy in the form of immune checkpoint inhibitors (ICI) have expanded treatment options for patients with an otherwise poor prognosis. Despite these gains, ICIs and 90Y-RE each have key limitations with low objective response rates and persistent hazard of out-of-field recurrence, respectively, and overall survival remains low. However, each therapy's strength may mitigate the other's weakness, making them potentially ideal partners for combination treatment strategies. This review discusses the scientific and clinical rationale for combining 90Y-RE with ICIs, highlights early clinical trial data on its safety and effectiveness, and proposes key issues to be addressed in this emerging field. With optimal strategies, combination therapies can potentially result in increasing likelihood of durable and curative outcomes in later stage patients.

BACKGROUND: Lymphatic drainage from the arm may be altered after axillary lymph node dissection (ALND). Understanding these alterations is important as they may change standard surgical and radiation treatment in recurrent breast cancer or upper extremity skin cancers, including melanoma.

METHODS: Utilizing a single-institution planar and single photon emission computed tomography/computed tomography lymphoscintigraphy database, we identified patients with a diagnosis of upper extremity cutaneous melanoma from 2008 to 2023 who previously underwent ALND for cancer treatment and did not develop upper extremity cancer-related lymphedema. ALND patients were matched to control patients presenting with cutaneous melanomas at the same anatomic sites. Sentinel lymph nodes (SLNs) were compared between both groups.

RESULTS: Of 3628 upper extremity melanoma cutaneous patients, 934 met inclusion criteria, including 22 ALND and 912 control patients. Level I axillary SLN drainage was observed in 98% of controls and 27% of ALND patients (p < 0.001). Level II axillary SLN drainage was observed in 3% of controls and 27% of ALND patients (p < 0.001). Level III axillary SLN drainage was observed in 1% of controls and 32% of ALND patients (p < 0.001). Epitrochlear SLN drainage was observed in 9% of controls and 32% of ALND patients, respectively (p < 0.046). Brachial SLN drainage was observed in 4% of controls and 23% of ALND patients (p < 0.001).

CONCLUSIONS: Distinct changes in functional lymphatic drainage were seen between the arms of patients who previously underwent ALND versus control patients. Levels II and III axillary, epitrochlear, and brachial nodes are possible sites of metastatic disease that should be considered in patients with a prior ALND.